Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Coronary Syndrome
- Arterial Occlusive Diseases
- Arteriosclerosis
- Cardiovascular Diseases
- Coronary (Artery) Disease
- Coronary Disease
- Heart Diseases
- Myocardial Ischemia
- Syndrome Heart Disease
- Vascular Diseases
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: All patients will be randomly divided into the treatment group and control group on a 1:1 basis, based on a complete randomization. The treatment group will use aspirin + clopidogrel dual anti-platelet therapy for 12 months, and the control group will use aspirin monotherapy for 12 months.Masking: None (Open Label)Masking Description: This is an open-label trial, and the investigators and subjects will not be blinded. Under these conditions, the following methods will be employed to minimize bias: Clinical Endpoint Committee (CEC) is an independent group of experts that reviews clinical trial data in order to give expert opinions about clinical safety or efficacy events of interest; The statisticians are independent and blind to the grouping information. Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04624854
- Collaborators
- Chinese Society of Cardiology
- Lepu Medical Technology (Beijing) Co., Ltd.
- Investigators
- Principal Investigator: Bo Yu, M.D.,FACC The Second Affiliated Hospital of Harbin Medical University